Table 1. A summary of the progression-free survival analysis in 5 key signalling pathways.
| Pathway/family | Source | Total # Genes | Total # CGIs | # loci (130–6000bp) | SGCTG cohort (n=150) | TCGA cohort (n=311) | Genes | |
|---|---|---|---|---|---|---|---|---|
| # loci Univariate PFS analysis P<0.01 and FDR<10% |
# loci Multivariate PFS analysis p<0.05 |
# validated loci/ # loci on the array |
||||||
| Akt/mTOR | hsa041501 | 51 | 51 | 78 | 6 | 4 | 2/3 | VEGFA, VEGFB* |
| p53 | hsa041151 | 68 | 87 | 140 | 14 | 10 | 1/4 | SESN2 |
| BRCA1/2 | Biocompare2 | 64 | 72 | 101 | 10 | 7 | 3/5 | E2F1, FANCA, HDAC11 |
| Redox | Manually curated | 48 | 44 | 63 | 5 | 5 | 2/3 | PRDX2, GPX4* |
| HR | ko034401 | 35 | 31 | 45 | 3 | 3 | 2/2 | RECQL4, RAD54L* |
1
Kyoto Encyclopaedia of Genes and Genomes (KEGG)
2
Biocompare website: http://www.biocompare.com/
*
The locus is significantly correlated with response measured by RECIST criteria (version 1.0) (logistic regression, p<0.05)